AXIS
FORENSIC TOXICOLOGY

See our Test Catalog at www.axisfortox.com
for more information.

SYNTHETIC CANNABINOIDS (K2/SPICE)

Axis Forensic Toxicology leads the industry in designer drug testing

AXIS' SYNTHETIC CANNABINOIDS PANEL INCLUDES THE NEWEST GENERATION DESIGNER DRUG COMPOUNDS

Evolution of Synthetic Cannabinoids

- After a dramatic rise in the number and frequency of synthetic cannabinoids in 2015 – 2017, Axis has observed some changes to the incidence of synthetic cannabinoids over the last few years.
- During 2017 – 2019, 5F-ADB, ADB-FUBINACA, and FUB-AMB dominated the drug market. Another large shift was perceived in 2019 – 2020 when 4CN-CUMYL-BINACA, 4F-MDMB-BINACA, and 5F-MDMB-PICA emerged and became prevalent.
- While 5F-ADB, ADB-FUBINACA, and FUB-AMB have now decreased into relative obscurity, other substances have replaced them. As of the most recent United States Drug Enforcement Administration (DEA) data from NFLIS-DRUG and Emerging Threats Reports, these newly emerged compounds (4F-MDMB-BICA, ADB-BINACA, and MDMB-4en-PINACA), alongside already established substances (4CN-CUMYL-BINACA, 4F-MDMB-BINACA, and 5F-MDMB-PICA) accounted for the vast majority of reported synthetic cannabinoids in 2020 – 2022.

Analyte	Reporting Limit (ng/mL)
4CN-CUMYL-BINACA	0.5
4F-MDMB-BINACA	0.5
ADB-4en-PINACA	0.5
ADB-BINACA	0.5
4F-MDMB-BICA Metabolite	2.0
5F-MDMB-PICA Metabolite	2.0
MDMB-4en-PINACA Metabolite	2.0

Screening for synthetic cannabinoids is now included with Analyte Assurance™, a feature of Axis' Comprehensive Panels.

SMR313 V3.0 Effective Date: 1/22/2024